EPIRUS Biopharmaceuticals, Inc.
DelistedCIK 1135906fmd_0ZHHMG63XJHFJ5H8FK77FWVX65Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2016, 25 periods
Latest annual · FY2013
Millions- Total revenues
- 15
- Operating income
- (52)
- Net income
- (52)
- Free cash flow
- (47)
Latest quarter · Q1 FY2016
Millions- Operating income
- (16)
- Net income
- (16)
- Free cash flow
- (11)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2010 to FY2013
- -31.9%
- Net income, 5 yearsFY2010 to FY2015
- n/m
EPIRUS Biopharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2015 | FY2014 | Change | Source |
|---|---|---|---|---|
| Operating income | -$52.3 million | -$39.3 million | 10-K 2016-03-29 · proof | |
| Net income | -$52.2 million | -$41.8 million | 10-K 2016-03-29 · proof | |
| Cash from operating activities | -$46.6 million | -$35.5 million | 10-K 2016-03-29 · proof | |
| Free cash flow | -$47.1 million | -$35.7 million | 10-K 2016-03-29 · proof | |
| Total assets | $72.3 million | $51.4 million | +40.7% | 10-K 2016-03-29 · proof |
| Total liabilities | $35.9 million | $19 million | +89.2% | 10-K 2016-03-29 · proof |
| Cash and cash equivalents | $31.5 million | $21.5 million | +46.8% | 10-K 2016-03-29 · proof |
- What was EPIRUS Biopharmaceuticals, Inc.'s operating income in fiscal 2015?
- EPIRUS Biopharmaceuticals, Inc. reported operating income of -$52.3 million for fiscal 2015 (the year ended Dec 31, 2015), against -$39.3 million the year before. Source: the 10-K filed with the SEC on Mar 29, 2016. SEC
- What was EPIRUS Biopharmaceuticals, Inc.'s net income in fiscal 2015?
- EPIRUS Biopharmaceuticals, Inc. reported net income of -$52.2 million for fiscal 2015 (the year ended Dec 31, 2015), against -$41.8 million the year before. Source: the 10-K filed with the SEC on Mar 29, 2016. SEC
- What was EPIRUS Biopharmaceuticals, Inc.'s cash from operating activities in fiscal 2015?
- EPIRUS Biopharmaceuticals, Inc. reported cash from operating activities of -$46.6 million for fiscal 2015 (the year ended Dec 31, 2015), against -$35.5 million the year before. Source: the 10-K filed with the SEC on Mar 29, 2016. SEC
- What was EPIRUS Biopharmaceuticals, Inc.'s free cash flow in fiscal 2015?
- EPIRUS Biopharmaceuticals, Inc. reported free cash flow of -$47.1 million for fiscal 2015 (the year ended Dec 31, 2015), against -$35.7 million the year before. Source: the 10-K filed with the SEC on Mar 29, 2016. SEC
- What are EPIRUS Biopharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2015, EPIRUS Biopharmaceuticals, Inc. reported total assets of $72.3 million, against $51.4 million a year earlier (+40.7%). Source: the 10-K filed with the SEC on Mar 29, 2016. SEC
- What are EPIRUS Biopharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2015, EPIRUS Biopharmaceuticals, Inc. reported total liabilities of $35.9 million, against $19 million a year earlier (+89.2%). Source: the 10-K filed with the SEC on Mar 29, 2016. SEC
- What are EPIRUS Biopharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2015, EPIRUS Biopharmaceuticals, Inc. reported cash and cash equivalents of $31.5 million, against $21.5 million a year earlier (+46.8%). Source: the 10-K filed with the SEC on Mar 29, 2016. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1135906&period_type=annual&limit=5"Information only, not investment advice.